80 articles with Clinigen
Expands operations of exclusive ‘on-demand’ supply service beyond the UK into France Enables continuity of supply for global clinical trial customers wanting EU product Long term partnerships between Accord Healthcare and both Clinical Services and Global Access, demonstrating strong position serving both pharma and HCPs’ needs
Xeris Pharmaceuticals Signs Exclusive Agreement With Clinigen to Supply and Distribute Gvoke™ Outside the U.S on a Named Patient Basis
Xeris Pharmaceuticals, Inc. announced an exclusive agreement with Clinigen Group plc to manage the supply and distribution of Gvoke™ outside of the United States where Gvoke is not currently licensed.
Clinigen Signs Exclusive Agreement with Xeris Pharmaceuticals to Supply and Distribute Gvoke™ Outside the US
Clinigen Group plc, the global pharmaceutical and services company, has signed an exclusive agreement with Xeris Pharmaceuticals, Inc. to manage the supply and distribution of Gvoke™ injection, a treatment for diabetes, outside the US.
Clinigen Group plc, the global pharmaceutical and services company acknowledges the presentation of results from the Phase I trial “Durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes in non -small cell lung cancer.” Ben C. Creelan MD, MS from the Thoracic Oncology, Immunology Program of the Moffitt Cancer and Research Institute presented at the American Association for Cancer Research virtual annual meeting on April 28, 2020.
Clinigen signs agreement with Iovance Biotherapeutics to supply Proleukin® (aldesleukin) for use in Tumor Infiltrating Lymphocyte (TIL) Clinical R&D
Proleukin is the first and only FDA approved IL-2 being used in development of T-Cell treatments
Clinigen and Orphazyme launch an Early Access Program for arimoclomol in patients with Niemann-Pick disease type C
Clinigen Group plc has partnered with Orphazyme A/S, a global biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, to introduce and administer an Early Access Program for arimoclomol in patients with Niemann-Pick disease type C in the US.
10/17/2019Companies from across the globe provide business and pipeline updates.
Clinigen Group plc has launched a Managed Access Program for Progenics Pharmaceuticals, Inc., an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, to provide AZEDRA® via a global Managed Access Program, outside the United States.
AZEDRA is not approved for use outside of the United States.
Clinigen Group plc, the global pharmaceuticals and services group, has published its full year results for the year ended 30 June 2019.
6/27/2019Biotech and pharma companies from across the globe share pipeline and business updates.
Clinigen - MHRA licenses two Melatonin products indicated for short-term jet-lag treatment in adults
Obtaining marketing authorisations for a previously unlicensed product is an example of the unlicensed to licensed strategy in the Commercial Medicines business and follows the successful launch of previous products in the portfolio, including Glycopyrronium Bromide Oral Solution.
Clinigen broadens partnership with Accord Healthcare to supply and distribute Cardioxane® and Savene® in Poland
Cardioxane is used as a cardio protectant with cancer chemotherapy treatment.
5/3/2019Biopharma companies make changes to their C-suite leadership teams, with hires at uBiome, Enzyre, Sobi, Amylyx, Mission Therapeutics, and more.
Clinigen K.K. and GC Pharma Announce Exclusive Licensing Agreement in Japan for Hunterase (Idursulfase-beta) ICV, Hunter Syndrome Drug
Clinigen K.K. and GC Pharma announced an exclusive licensing agreement in Japan to commercialize Hunterase ICV, a human recombinant iduronate-2-sulfatase used in enzyme replacement therapy for the treatment of Hunter syndrome.
Across parts of Europe, Asia and the rest of the globe, pharma and biotech companies have made strides and deals to advance their pipelines and technologies this week.
London-based Clinigen Group pc will now have full rights to Proleukin (aldesleukin, human recombinant interleukin-2). This morning, the U.K.-based pharmaceutical and services company struck a deal with Novartis to acquire the U.S. rights to the metastatic renal cell carcinoma treatment.
Clinigen Group plc announces that Professor Alan Boyd has been appointed as a Non-Executive Director with immediate effect.
Clinigen Group plc announces that it has today completed the acquisition of iQone Healthcare Holding ('iQone'), which was announced on 27 September 2018 (the "Acquisition").
Clinigen Group plc today announces that it has completed the acquisition of CSM Parent, Inc. ('CSM'), which was announced on 27 September 2018 (the "Acquisition").